EFFECTS OF DAPAGUFLOZIN ON BIOMARKERS, SYMPTOMS AND FUNCTIONAL STATUS IN 
PATIENTS WITH PRESERVED EJECTION FRACTION HEART fAILURE (PRESERVED-HF TRIAL) 
Protocol Number: D1690C00053 
PRESERVED-HF Protocol v3.0 Page 1 of67 
Version Date March 20,  2020
Protocol
[STUDY_ID_REMOVED]
